Document is current
Any future updates will be listed below
-
Authors
O’Cathail, Séan M. https://orcid.org/0000-0001-5574-9199
Davis, Steven
Holmes, Jane
Brown, Richard
Fisher, Kerry
Seymour, Leonard
Adams, Richard
Good, James
Sebag-Montefiore, David
Maughan, Tim
Hawkins, Maria A.
-
Funding
Funding for this research was provided by:
Cancer Research UK (C43735/A24474)
- License Information
-
More Information
Article History
Received: 24 January 2020
Accepted: 8 June 2020
First Online: 12 June 2020
Ethics approval and consent to participate
: The trial is sponsored by the University of Oxford and was approved by the South Central - Oxford B Research Ethics Committee (REC Reference: 18/SC/0583). Written, signed informed consent is required of all participants.
: Not applicable.
: PsiOxus Therapeutics are commercial collaborators who are part funding the study. LS and KF own equity in PsiOxus Therapeutics Ltd., which owns Enadenotucirev. RB is an employee of PsiOxus Therapeutics Ltd. Dr. Maughan reports grants from Medical Research Council, grants from Cancer Research UK; non-financial support and other from Astra Zeneca, personal fees from Pierre Fabre, outside the submitted work. All other authors declare no relevant conflict of interest.
